Abstract
4509 Background: To compare the efficacy of 4 cycles of T-BEP to 4 cycles of BEP in previously untreated patients (pts) with intermediate prognosis GCC. Methods: Pts were randomly assigned to receive either standard BEP (cisplatin 20 mg/m2 d1-5, etoposide100 mg/m2 d1-5, bleomycin 30 mg weekly) or T-BEP (paclitaxel 175 mg/m2 given as a 3-hours infusion on d1, before starting standard BEP. Pts on T-BEP received primary G-CSF prophylaxis. The study was designed as a randomized open-label phase II/III study. To show a 10% improvement in 3-year PFS (2-sided Logrank, α= 5%, 80% power), the study needed 498 patients (98 events planned), but closed with 337 due to slow accrual. Primary analysis is by intent-to-treat (ITT) at α=0.0455 (adjusted for interim). ClinicalTrials.gov id: NCT00003643. Results: Accrual was from 11/1998 to 04/2009. 169 pts were assigned BEP and 168 T-BEP. 13 pts on both arms were ineligible, mainly due to good prognosis GCC (8 on BEP, 6 on T-BEP). Of 5 pts ineligible due to poor risk GCC, 4 had been allocated T-BEP. Relative dose-intensity was > 97.7% for all drugs. T-BEP was well tolerated; 31 episodes of neutropenic fevers were reported on T-BEP (compared to 18 on BEP), but there were only 2 toxic deaths. After a median follow-up of 5.3 years, a total of 84 events occurred. PFS at 3-years (ITT) was 79.4% on T-BEP versus 71.1% on BEP, HR= 0.73 (CI: 0.47-1.13), logrank P = 0.153. PFS at 3-years in all eligible pts was 82.7% versus 70.1%, respectively, HR=0.60 (CI: 0.37-0.97) and statistically significant, logrank P = 0.03. Overall survival was not statistically different. Conclusions: The PFS intent-to-treat (primary efficacy) analysis is not statistically significant, but is negatively influenced by the uneven distribution of ineligible pts amongst the 2 treatment arms. The analysis of all eligible pts, however, shows a 12% superior 3-year PFS with T-BEP, which is statistically significant. This study demonstrates superior efficacy of T-BEP in the management of the intended intermediate prognosis GCC risk group. This is the first study to show superiority over standard BEP in this population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.